G
Grace Therapeutics, Inc. (GRCE)
NCM – Real vaqt narxi. Valyuta: USD
2.38
+0.01 (0.42%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
2.38
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 4:55 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.38
+0.01 (0.42%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
2.38
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 4:55 PM EDT
Grace Therapeutics, Inc. Kanadada noyob va kam uchraydigan kasalliklar uchun farmatsevtika mahsulotlarini ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniyaning asosiy mahsulot nomzodlari - bu anevrizmatik subaraxnoidal qon ketishini davolash uchun ishlab chiqilgan in'ektsion formulyatsiya bo'lgan GTX-104. Shuningdek, u Ataksiya-Telangiektaziya (A-T) ning nevrologik belgilarini yaxshilash uchun betametazonning og'iz orqali qo'llaniladigan shilliq qavat spreyi bo'lgan GTX-102; va postherpetik nevralgiya (PHN) bilan bog'liq og'riqni davolash uchun bupivakainning topikal bioyopishqoq plyonka hosil qiluvchi spreyi bo'lgan GTX-101ni ishlab chiqadi. Kompaniya avval Acasti Pharma Inc. nomi bilan tanilgan va 2024 yil oktyabr oyida Grace Therapeutics, Inc. deb nomini o'zgartirgan. Grace Therapeutics, Inc. 2002 yilda tashkil etilgan va shtab-kvartirasi Nyu-Jersi shtatining Prinston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board & Chief Medical Officer |
| Mr. Amresh Kumar Ph.D. | VP of Program Management |
| Mr. Prashant Kohli | CEO & Director |
| Mr. Robert J. DelAversano CPA | VP of Finance and Principal Financial & Accounting Officer |
| Ms. Carrie D'Andrea | VP of Clinical Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-18 | 8-K | ef20076431_form8k.htm |
| 2026-06-05 | 8-K | ef20075612_8k.htm |
| 2026-04-27 | 8-K | ef20071554_8k.htm |
| 2026-04-23 | 8-K | ef20070593_8k.htm |
| 2026-02-12 | 8-K | ef20064916_8k.htm |
| 2026-02-12 | 10-Q | ef20060621_10q.htm |
| 2026-01-12 | 8-K | ef20062691_8k.htm |
| 2025-11-17 | 10-Q/A | ef20059408_10qa.htm |
| 2025-11-13 | 8-K | ef20058656_8k.htm |
| 2025-10-23 | 8-K | ef20057547_8k.htm |